Visual analysis of posttherapy whole-body scans and SPECT/CT scans demonstrated significant uptake and retention of 177Lu-FAP-2286 in tumor lesions on delayed imaging (72 h–10 d after injection) in all patients (SUVs of 177Lu-FAP-2286 in tumor lesions are displayed in Supplemental Table 3, and those of the kidneys are in Supplemental Table 4; representative examples are shown in Figs. 1 and 2, and the whole-body scans of patients 1–3, 5, and 7–11 are in Supplemental Fig. 1). Here, FAP is linked to neoplasm.